CITI/CALL/VERTEX PHARMACEUTICALS/400/0.1/20.06.24 | Delayed Deutsche Boerse AG 08:05:05 2024-06-03 EDT | ||
| 5.36 EUR | +9.16% |
|
| 1 month | +231.76% | ||
| 3 months | +18.03% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-06-03 | 5.36 | +9.16% |
| 24-05-31 | 4.91 | +21.53% |
| 24-05-30 | 4.04 | -6.05% |
| 24-05-29 | 4.3 | -7.53% |
| 24-05-28 | 4.65 | -20.38% |
Delayed Quote Deutsche Boerse AG
Last update June 03, 2024 at 08:05 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Citi
|
| WKN | KH8AW5 |
| ISIN | DE000KH8AW52 |
| Date issued | 2023-07-24 |
| Strike | 400 $ |
| Maturity | 2024-06-20 (17 Days) |
| Parity | 10 : 1 |
| Emission price | 2.81 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.16 € |
|---|---|
| Lowest since issue | 1.26 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
455.3
USD
Average target price
463.5
USD
Spread / Average Target
+1.80%
- Stock Market
- Warrants
- Warrant
